Last-Hope drug offered for devastating skin flares
NCT ID NCT05239039
Summary
This program provided early access to an intravenous drug called spesolimab for adults in China suffering from severe, sudden flare-ups of Generalized Pustular Psoriasis (GPP), a rare and serious skin disease. It was for patients who had no other satisfactory treatment options available. Participants received one or two infusions to control the flare and were monitored for about four months, with the possibility of repeat treatment if a new flare occurred.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital
Beijing, 100050, China
-
Dermatology Hospital, Chinese Academy of Medical Sciences
Nanjing, 210000, China
-
Hangzhou Third People's Hospital
Hangzhou, 310013, China
-
Shandong Provincial Hospital of Dermatology
Jinan, 250063, China
-
Shanghai Skin Disease Hospital
Shanghai, 200000, China
-
Southern Medical University Dermatology Hospital
Guangzhou, 510091, China
-
The First Hospital of China Medical University
Shenyang, 110001, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, 310009, China
-
The University of Hong Kong-Shenzhen Hospital
Shenzhen, 518053, China
-
Tianjin Medical University General Hospital
Tianjin, 30052, China
-
West China Hospital
Chengdu, 610041, China
-
Wuhan Union Hospital
Wuhan, 430022, China
Conditions
Explore the condition pages connected to this study.